ArticleBMC infectious diseases2025
Prevalence of human papillomavirus (HPV) genotypes in patients with clinical symptoms in Kermanshah, western Iran: a cross-sectional study.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Epidemiology of Human Papillomavirus in the Middle East and North Africa: A Review of Genotypic Prevalence, Vaccination Challenges, and Non-Cervical Clinical Outcomes.Diseases (Basel, Switzerland) · 2026Review
- Epidemiology and genotype distribution of human papillomavirus (HPV) in Northern Iran.BMC infectious diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundHuman papillomavirus (HPV) is the cause of genital tract infections. This virus can cause diverse diseases, such as warts and anogenital cancers. Despite the WHO recommendations for HPV vaccination, there is no public HPV vaccination plan in Iran. Therefore, the prevalence of HPV infection in Iran is greater than that in countries with vaccination programs.
objectivesWe aimed to evaluate the prevalence of various HPV genotypes in genital specimens from patients with clinical symptoms in western Iran.
methodsBetween 2015 and 2023, 818 vaginal swabs and 26 genital wart samples from females and 28 genital wart samples from males were transferred to the Pars Pathobiology Laboratory (Kermanshah Province) for HPV evaluation. HPV genotyping was performed with two real-time PCR kits and one reverse hybridization kit during the study.
resultsGenerally, 38.9% (340/872) of the participants were HPV positive. The prevalence rates of HPV in female vaginal swabs and genital wart samples were 37.4% (306/818) and 61.5% (16/26), respectively; however, the prevalence for males was 64.3% (18/28). The most common high-risk genotype was HPV50 (51, 52, 53, 56, 58, and 59) (26.5%), and among the low-risk genotype was HPV6 (62.9%).
conclusionsThe prevalence of HPV-positive patients was greater than that in some neighboring countries and other regions of Iran. This high prevalence may be due to a lack of public vaccination. Therefore, we should conduct regular screenings for all age groups of females. Males can act as carriers for the virus, and informing men about this infection is essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.